Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, has announced that it has raised US$150 million in Series B funding. Led by Cormorant Asset Management, the round included an investment from Goldman Sachs Asset Management and existing investors. Latham & Watkins LLP advised Goldman Sachs […]
The post Latham & Watkins Advises Goldman Sachs Asset Management in US$150 Million Series B Funding for Rapport Therapeutics appeared first on Legal Desire Media and Insights.